Global Technology Report

New Hope Emerges for Diabetics with Foot Ulcers

 Breaking News
  • No posts were found

New Hope Emerges for Diabetics with Foot Ulcers

January 27
03:46 2022
New Hope Emerges for Diabetics with Foot Ulcers

With our current standard of care in the United States, four out of five patients who suffer from diabetic foot ulcer wounds get amputated from the knee down. These ulcers are responsible for more than 80% of all diabetes-related lower-leg amputations and occur in around 15% of diabetic patients. Even with today’s most advanced tools and methods, the current reality is a harsh one for diabetics who have suffered (or who will suffer) from wounds such as these.

Diabetic foot ulcers are most commonly caused by injured feet, damage to the nerves, poor circulation, and high blood sugar levels.  While the healing of wounds is a natural process, some metabolic disorders, such as diabetes mellitus, delay the typical pace of the wound healing process. And, given the erratic nature of the disease, healing can be somewhat interrupted as the body prioritizes greater stressors to its physiology. This is why a new technology, such as Circularity Healthcare’s, is so critical: Diabetics with foot ulcers simply need a low-cost method to expedite the healing process so that their wounds are short-lived and treated promptly.

DFU treatments usually include the control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy. Hyperbaric oxygen therapy may be beneficial but it is costly.

However, for a solid decade, new clinical evidence has been demonstrating that a unique new health technology from Circularity Healthcare heals and closes 90% or more of the most severe wounds in approximately four to eight weeks. This is a fast recovery time, and the cost for this new technology is only about 10% of any other existing healing modality. After three highly successful diabetic foot ulcer pivotal trials, Circularity Healthcare is now in expanded pivotal trials for updated FDA clearance with its D’OXYVA® (deoxyhemoglobin vasodilator) noninvasive transdermal drug delivery system at 18 of the 20 top-ranked U.S. universities.

These clinical trials are demonstrating tremendous possibilities for saving time, expense, and unnecessary suffering for those with diabetic foot ulcer wounds. Circularity Healthcare is eager to revolutionize treatment with their exciting new therapy and expected FDA approval.

Media Contact
Company Name: Circularity Healthcare
Contact Person: Mark McCarthy
Email: Send Email
Phone: (855) 5-DOXYVA
Country: United States